Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | BRD2 | P25440 | 18/20 | 1.00 |
| ▸ | BRD3 | Q15059 | 18/20 | 1.00 |
| ▸ | TRIM24 | O15164 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TAF1 | P21675 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 1/20 | 1.00 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 1.00 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 1.00 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11978889 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL1907498 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL29520173 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL22704705 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL19985767 | 0.93 | BRD4 (0.87) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL16774251 | 0.92 | BRD4 (0.85) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL16774302 | 0.92 | BRD4 (0.86) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL223735 | 0.92 | BRD4 (0.85) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL15981317 | 0.92 | BRD4 (0.85) | BRD4BRD2BRD3TRIM24CYP3A4 | |
| SCHEMBL221384 | 0.92 | BRD4 (0.85) | BRD4BRD2BRD3TRIM24CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564559-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | ORYZON GENOMICS, S.A. (ES) | 2026-03-03 | — | — | US | claimed |
| EP-4684836-A2 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | Oryzon Genomics, S.A. (ES) | 2026-01-28 | — | — | EP | claimed |
| EP-3429571-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | ORYZON GENOMICS SA (ES) | 2025-10-08 | — | — | EP | claimed |
| CN-119874724-A | Novel recruitment element of ubiquitin ligase and application thereof | 深圳领济生物科技有限公司 | 2025-04-25 | — | — | CN | claimed |
| US-20250116671-A1 | Kinase Activity In Tumors | INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2025-04-10 | — | — | US | claimed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| US-20240264151-A1 | Methods and Compositions for Treating Diseases Associated with Exhausted T Cells | UNIV PENNSYLVANIA (US) | 2024-08-08 | — | — | US | claimed |
| CN-117159715-A | New use of inhibitor and inhibitor screening model | 中国农业大学 | 2023-12-05 | — | — | CN | claimed |
| EP-3468559-B1 | METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-11-22 | — | — | EP | claimed |
| US-20230330238-A1 | CHIMERIC CONJUGATES FOR DEGRADATION OF VIRAL AND HOST PROTEINS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2023-10-19 | — | — | US | claimed |
| US-20220047596-A1 | COMBINATION OF PARP INHIBITOR AND BRD4 INHIBITOR FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-17 | — | — | US | claimed |
| US-20180346988-A1 | ZNF532 FOR DIAGNOSIS AND TREATMENT OF CANCER | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-12-06 | — | — | US | claimed |
| US-20170007595-A1 | NSD3 INHIBITORS FOR TREATMENT OF CANCERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-01-12 | — | — | US | claimed |
| WO-2016179222-A1 | ZNF532 FOR DIAGNOSIS AND TREATMENT OF CANCER | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-11-10 | — | — | WO | claimed |
| WO-2015112809-A2 | NSD3 INHIBITORS FOR TREATMENT OF CANCERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-30 | — | — | WO | claimed |
| EP-2699550-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-06-10 | — | — | EP | claimed |
| EP-2496235-A1 | BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | claimed |
| US-20120208800-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | claimed |
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | claimed |
| WO-2011054843-A1 | BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | BRD4, BRDT, BRPF3 | BRD4 1/4885BRD2 5/4885BRD3 4/4885 |
| US-20120208800-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | BRD4, BRD3, BRPF3 | BRD4 1/4885BRD2 4/4885BRD3 2/4885 |
| US-12564559-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | EZH2, BRDT, DOT1L | BRD4 17/4885BRD2 46/4885BRD3 25/4885 |
| US-20170007595-A1 | NSD3 INHIBITORS FOR TREATMENT OF CANCERS | NSD3, NSD2, BRD3 | BRD4 5/4885BRD2 15/4885BRD3 3/4885 |
| US-20230330238-A1 | CHIMERIC CONJUGATES FOR DEGRADATION OF VIRAL AND HOST PROTEINS AND METHODS OF USE | MDM2, TP53, USP19 | BRD4 50/4885BRD2 103/4885BRD3 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.